Gregory P. Botta

1.1k total citations
36 papers, 786 citations indexed

About

Gregory P. Botta is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Gregory P. Botta has authored 36 papers receiving a total of 786 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 11 papers in Cancer Research and 9 papers in Surgery. Recurrent topics in Gregory P. Botta's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Gregory P. Botta is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Gregory P. Botta collaborates with scholars based in United States, Japan and Netherlands. Gregory P. Botta's co-authors include Peter I. Lelkes, Michael Frohbergh, Caroline L. Schauer, Anna Katsman, P. Lazarovici, Ulrike G. K. Wegst, Anil K. Rustgi, Maximilian Reichert, Steffen Heeg and Mauricio J. Reginato and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Biomaterials.

In The Last Decade

Gregory P. Botta

33 papers receiving 781 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory P. Botta United States 12 297 274 254 172 155 36 786
Yoshinosuke Hamada Japan 20 255 0.9× 140 0.5× 231 0.9× 365 2.1× 168 1.1× 36 1.0k
Jacqui McGovern Australia 19 480 1.6× 185 0.7× 148 0.6× 230 1.3× 203 1.3× 44 1.0k
Stephanie Grainger United States 17 237 0.8× 124 0.5× 221 0.9× 469 2.7× 243 1.6× 33 995
Yunlang She China 16 186 0.6× 152 0.6× 222 0.9× 301 1.8× 222 1.4× 34 949
Duohui Jing Germany 14 117 0.4× 172 0.6× 137 0.5× 274 1.6× 76 0.5× 22 905
Matthew P. Ablett United Kingdom 10 197 0.7× 400 1.5× 208 0.8× 477 2.8× 101 0.7× 10 1.2k
Shengwei Han China 13 563 1.9× 104 0.4× 155 0.6× 332 1.9× 194 1.3× 20 1.0k
Qiusheng Shi China 16 448 1.5× 78 0.3× 259 1.0× 263 1.5× 78 0.5× 49 904
Naser Ahmadbeigi Iran 20 341 1.1× 272 1.0× 238 0.9× 446 2.6× 349 2.3× 63 1.4k
Manuela Salerno Italy 19 211 0.7× 286 1.0× 142 0.6× 457 2.7× 175 1.1× 41 1.1k

Countries citing papers authored by Gregory P. Botta

Since Specialization
Citations

This map shows the geographic impact of Gregory P. Botta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory P. Botta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory P. Botta more than expected).

Fields of papers citing papers by Gregory P. Botta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory P. Botta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory P. Botta. The network helps show where Gregory P. Botta may publish in the future.

Co-authorship network of co-authors of Gregory P. Botta

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory P. Botta. A scholar is included among the top collaborators of Gregory P. Botta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory P. Botta. Gregory P. Botta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dumbrava, Ecaterina E., Syma Iqbal, Gregory P. Botta, et al.. (2025). A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.. Journal of Clinical Oncology. 43(4_suppl). 828–828.
2.
Botta, Gregory P., Joseph Chao, H. Ma, et al.. (2024). Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. Journal for ImmunoTherapy of Cancer. 12(2). e007927–e007927. 15 indexed citations
3.
Chakrabarti, Sakti, Stacey A. Cohen, Antony Tin, et al.. (2024). Prognostic value of circulating tumor DNA (ctDNA) testing in patients (pts) with rectal cancer after neoadjuvant therapy (NAT) and surgery.. Journal of Clinical Oncology. 42(3_suppl). 212–212. 1 indexed citations
4.
Shaya, Justin, Shumei Kato, Jacob J. Adashek, et al.. (2023). Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. npj Genomic Medicine. 8(1). 1–1. 20 indexed citations
5.
Cohen, Stacey A., Pashtoon Murtaza Kasi, Vasily N. Aushev, et al.. (2023). Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.. Journal of Clinical Oncology. 41(4_suppl). 5–5. 11 indexed citations
6.
Choi, Sharon, Razelle Kurzrock, Thomas J. O’Keefe, et al.. (2023). BTLA transcriptomic expression correlates with high levels of PD-1, PD-L2, and CTLA-4 checkpoints and with its ligand, HVEM, across diverse solid cancers.. Journal of Clinical Oncology. 41(16_suppl). e14641–e14641.
7.
Baumgartner, Joel & Gregory P. Botta. (2023). Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases. Journal of Gastrointestinal Cancer. 55(1). 41–46. 8 indexed citations
8.
Huffman, Brandon M., Vasily N. Aushev, Joseph Chao, et al.. (2022). Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO Precision Oncology. 6(6). e2200420–e2200420. 36 indexed citations
9.
Botta, Gregory P., et al.. (2022). Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients. Cancer Medicine. 12(7). 7713–7723. 6 indexed citations
10.
Louie, Bryan H., Shumei Kato, Ki Hwan Kim, et al.. (2022). Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. npj Precision Oncology. 6(1). 67–67. 11 indexed citations
11.
Mendoza, Tatiana Hurtado de, Evangeline Mose, Gregory P. Botta, et al.. (2021). Tumor-penetrating therapy for β5 integrin-rich pancreas cancer. Nature Communications. 12(1). 1541–1541. 53 indexed citations
12.
Botta, Gregory P., Shumei Kato, Hitendra Patel, et al.. (2021). SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 6(18). 50 indexed citations
13.
Bao, Fei, et al.. (2021). Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC). BMC Gastroenterology. 21(1). 340–340. 3 indexed citations
14.
Kasi, Pashtoon Murtaza, Farshid Dayyani, Gregory P. Botta, et al.. (2021). Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.. Journal of Clinical Oncology. 39(15_suppl). 4103–4103. 6 indexed citations
15.
Botta, Gregory P., et al.. (2017). Advances on immunotherapy in genitourinary and renal cell carcinoma. Translational Cancer Research. 6(1). 17–29. 9 indexed citations
16.
Botta, Gregory P., Maximilian Reichert, Mauricio J. Reginato, et al.. (2013). ERK2-regulated TIMP1 Induces Hyperproliferation of K-RasG12D-Transformed Pancreatic Ductal Cells. Neoplasia. 15(4). 359–IN1. 17 indexed citations
17.
Reichert, Maximilian, Shigetsugu Takano, Steffen Heeg, et al.. (2013). Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nature Protocols. 8(7). 1354–1365. 64 indexed citations
18.
Frohbergh, Michael, Anna Katsman, Gregory P. Botta, et al.. (2012). Electrospun hydroxyapatite-containing chitosan nanofibers crosslinked with genipin for bone tissue engineering. Biomaterials. 33(36). 9167–9178. 320 indexed citations
19.
Botta, Gregory P., Mauricio J. Reginato, Maximilian Reichert, Anil K. Rustgi, & Peter I. Lelkes. (2011). Constitutive K - Ras G12D Activation of ERK2 Specifically Regulates 3D Invasion of Human Pancreatic Cancer Cells via MMP-1. Molecular Cancer Research. 10(2). 183–196. 38 indexed citations
20.
Botta, Gregory P., et al.. (2006). Real-time assessment of three-dimensional cell aggregation in rotating wall vessel bioreactors in vitro. Nature Protocols. 1(4). 2116–2127. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshinosuke Hamada Breakdown of academic impact, for papers by Jacqui McGovern Breakdown of academic impact, for papers by Stephanie Grainger Breakdown of academic impact, for papers by Yunlang She Breakdown of academic impact, for papers by Duohui Jing Breakdown of academic impact, for papers by Matthew P. Ablett Breakdown of academic impact, for papers by Shengwei Han Breakdown of academic impact, for papers by Qiusheng Shi Breakdown of academic impact, for papers by Naser Ahmadbeigi Breakdown of academic impact, for papers by Manuela Salerno
Rankless by CCL
2026